WISE Closes Oversubscribed Series D Financing Round of 30 Million Euros
Summary
WISE S.p.A., a medical device company specializing in implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interfaces, announced the closing of an oversubscribed Series D financing round totaling 30 million euros. ENEA Tech and Biomedical, an Italian foundation for biomedical innovation, joined as a strategic new investor alongside existing partners. The funds will accelerate development and clinical adoption of WISE's Heron electrode for spinal cord stimulation, including regulatory certification and first-in-human studies. The financing also supports WISE's broader electrode portfolio across chronic pain and neural interface markets.
Why it matters
This significant European funding round highlights continued investor confidence in next-generation neural interface technology. The Heron electrode's unique combination of targeted directional stimulation with minimally invasive percutaneous implantation could meaningfully advance spinal cord stimulation therapy for chronic pain patients while reducing surgical complexity.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial